{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:56:17Z","timestamp":1791561377908,"version":"4.3.4"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Preclinical studies suggest that stabilization of hypoxia-inducible factor (HIF) may attenuate reperfusion injury.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine whether oral roxadustat, a HIF-prolyl hydroxylase inhibitor, reduced infarct size when administered after reperfusion among patients with ST-segment elevation myocardial infarction (STEMI).<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This phase 2, open-label, randomized clinical trial\u2014Effect of Roxadustat in Acute Myocardial Infarction (ROXAMI)\u2014enrolled adults with STEMI undergoing primary percutaneous coronary intervention (PCI) at a single tertiary medical center between April 1, 2021, and March 31, 2024, with follow-up through 1 year.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Oral roxadustat (100 mg, 3 times per week for 2 weeks), initiated within 2 hours after primary PCI, or standard care alone.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n \n The primary end point was infarct size as a percentage of the left ventricle at 30 days measured by late gadolinium enhancement on [\n 68<\/jats:sup>\n Ga]Ga-DOTA-FAPI-04 positron emission tomography (PET) and magnetic resonance imaging (MRI). Prespecified secondary end points included major adverse cardiovascular events, myocardial injury markers, echocardiographic parameters, and myocardial fibroblast activation parameters on [\n 68<\/jats:sup>\n Ga]Ga-DOTA-FAPI-04 PET and MRI. The primary efficacy analysis for infarct size was conducted in the modified intention-to-treat population.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 158 randomized patients (mean [SD] age, 63.6 [11.0] years; 133 men [84.2%]; 79 randomized to each group), 148 (93.7%; 72 roxadustat and 76 control) had evaluable imaging for the primary outcome. For the primary end point, mean (SD) infarct size did not significantly differ between the roxadustat and control groups (23.3% [12.2%] vs 22.0% [12.2%]; mean difference, 1.3 percentage points; 95% CI, \u22122.7 to 5.3 percentage points;\n P<\/jats:italic>\n \u2009=\u2009.51). Major adverse cardiovascular events occurred in 3 of 79 patients (3.8%) in the roxadustat group and 7 of 79 (8.9%) in the control group (hazard ratio, 0.42; 95% CI, 0.11-1.63;\n P<\/jats:italic>\n \u2009=\u2009.21). In multiplicity-unadjusted secondary analyses, adjusted between-group differences at 12 months were 2.9 percentage points (95% CI, 0.4-5.3 percentage points;\n P<\/jats:italic>\n \u2009=\u2009.02) for the change in left ventricular ejection fraction (mean [SD]: roxadustat, 3.4% [0.9%] vs control, 0.5% [0.9%]) and \u22124.5 mL\/m\n 2<\/jats:sup>\n (95% CI, \u22128.9 to \u22120.1 mL\/m\n 2<\/jats:sup>\n ;\n P<\/jats:italic>\n \u2009=\u2009.045) for left ventricular end-diastolic volume index (mean [SD]: roxadustat, 1.2 [1.6] mL\/m\n 2<\/jats:sup>\n vs control, 5.7 [1.6] mL\/m\n 2<\/jats:sup>\n ). The incidence of prespecified safety end points did not differ between the roxadustat and control groups.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this randomized clinical trial of patients with STEMI, roxadustat administration after PCI did not significantly reduce infarct size at 30 days compared with control. Secondary ventricular remodeling findings were exploratory and require confirmation.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT04803864<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.37953","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:30:23Z","timestamp":1791559823000},"page":"e2637953","source":"Crossref","is-referenced-by-count":0,"title":["Roxadustat Treatment After PCI Among Patients With ST-Segment Elevation Myocardial Infarction"],"prefix":"10.1001","volume":"9","author":[{"given":"Weiwei","family":"Quan","sequence":"first","affiliation":[{"name":"Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"Institute of Cardiovascular Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"Collaboration Innovation Center for Molecular Imaging of Precision Medicine, Ruijin Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqi","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinzhou","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengbin","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghua","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Ni","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyang","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuehua","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuezheng","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiang","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"issue":"11","key":"zoi261023r1","first-page":"774","article-title":"The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge.","volume":"38","author":"Heusch","year":"2017","journal-title":"Eur Heart J"},{"issue":"1","key":"zoi261023r2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/S0735-1097(01)01711-9","article-title":"The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis.","volume":"39","author":"Burns","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"zoi261023r3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/ehjcvp\/pvae013","article-title":"New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023.","volume":"10","author":"Tamargo","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"9861","key":"zoi261023r4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/S0140-6736(12)60916-7","article-title":"Cardioprotection: chances and challenges of its translation to the clinic.","volume":"381","author":"Heusch","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"zoi261023r5","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1161\/CIRCRESAHA.119.314679","article-title":"Cardioprotection beyond infarct size reduction.","volume":"124","author":"Heusch","year":"2019","journal-title":"Circ Res"},{"issue":"7","key":"zoi261023r6","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1089\/ars.2010.3769","article-title":"Disruption of hypoxia-inducible transcription factor-prolyl hydroxylase domain-1 (PHD-1-\/-) attenuates ex vivo myocardial ischemia\/reperfusion injury through hypoxia-inducible factor-1a transcription factor and its target genes in mice.","volume":"15","author":"Adluri","year":"2011","journal-title":"Antioxid Redox Signal"},{"issue":"13","key":"zoi261023r7","doi-asserted-by":"publisher","first-page":"11185","DOI":"10.1074\/jbc.M110.186809","article-title":"Cardiomyocyte-specific prolyl-4-hydroxylase domain 2 knock out protects from acute myocardial ischemic injury.","volume":"286","author":"H\u00f6lscher","year":"2011","journal-title":"J Biol Chem"},{"key":"zoi261023r8","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.yjmcc.2015.01.007","article-title":"Depletion of PHD3 protects heart from ischemia\/reperfusion injury by inhibiting cardiomyocyte apoptosis.","volume":"80","author":"Xie","year":"2015","journal-title":"J Mol Cell Cardiol"},{"issue":"Pt A","key":"zoi261023r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113097","article-title":"The activation of the HIF-1a-VEGFA-Notch1 signaling pathway by Hydroxysafflor yellow A promotes angiogenesis and reduces myocardial ischemia-reperfusion injury.","volume":"142","author":"Ge","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"23","key":"zoi261023r10","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1161\/CIRCULATIONAHA.123.064332","article-title":"MDM2 regulation of HIF signaling causes microvascular dysfunction in hypertrophic cardiomyopathy.","volume":"148","author":"Shridhar","year":"2023","journal-title":"Circulation"},{"issue":"11","key":"zoi261023r11","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1016\/j.jacc.2005.08.045","article-title":"Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse.","volume":"46","author":"Kido","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"zoi261023r12","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/cvr\/cvq256","article-title":"Mitochondrial reprogramming through cardiac oxygen sensors in ischaemic heart disease.","volume":"88","author":"Cadenas","year":"2010","journal-title":"Cardiovasc Res"},{"issue":"6","key":"zoi261023r13","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1253\/circj.CJ-19-1039","article-title":"Roxadustat markedly reduces myocardial ischemia reperfusion injury in mice.","volume":"84","author":"Deguchi","year":"2020","journal-title":"Circ J"},{"issue":"13","key":"zoi261023r14","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.3390\/cells13131074","article-title":"Roxadustat attenuates adverse remodeling following myocardial infarction in mice.","volume":"13","author":"Zaruba","year":"2024","journal-title":"Cells"},{"issue":"17","key":"zoi261023r15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI137557","article-title":"HIF in the heart: development, metabolism, ischemia, and atherosclerosis.","volume":"131","author":"Knutson","year":"2021","journal-title":"J Clin Invest"},{"issue":"18","key":"zoi261023r16","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1161\/hc4301.097193","article-title":"Inhibition of collagen synthesis with prolyl 4-hydroxylase inhibitor improves left ventricular function and alters the pattern of left ventricular dilatation after myocardial infarction.","volume":"104","author":"Nwogu","year":"2001","journal-title":"Circulation"},{"issue":"2","key":"zoi261023r17","doi-asserted-by":"publisher","first-page":"H542","DOI":"10.1152\/ajpheart.00089.2005","article-title":"HIF-1 activation attenuates postischemic myocardial injury: role for heme oxygenase-1 in modulating microvascular chemokine generation.","volume":"289","author":"Ockaili","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"zoi261023r18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/FJC.0b013e3181e2bfef","article-title":"Chronic inhibition of hypoxia-inducible factor prolyl 4-hydroxylase improves ventricular performance, remodeling, and vascularity after myocardial infarction in the rat.","volume":"56","author":"Bao","year":"2010","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"zoi261023r19","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1161\/CIRCULATIONAHA.107.758516","article-title":"Hypoxia-inducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning.","volume":"118","author":"Eckle","year":"2008","journal-title":"Circulation"},{"issue":"4","key":"zoi261023r20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ejheart.2005.10.009","article-title":"Stabilization of hypoxia inducible factor rather than modulation of collagen metabolism improves cardiac function after acute myocardial infarction in rats.","volume":"8","author":"Philipp","year":"2006","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"zoi261023r21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s00395-019-0725-2","article-title":"Things get broken: the hypoxia-inducible factor prolyl hydroxylases in ischemic heart disease.","volume":"114","author":"Schreiber","year":"2019","journal-title":"Basic Res Cardiol"},{"issue":"11","key":"zoi261023r22","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","article-title":"Roxadustat for anemia in patients with kidney disease not receiving dialysis.","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"zoi261023r23","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","article-title":"Roxadustat treatment for anemia in patients undergoing long-term dialysis.","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi261023r24","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/ndt\/gfab191","article-title":"Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, open-label, active-controlled study (DOLOMITES).","volume":"36","author":"Barratt","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"20","key":"zoi261023r25","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"22","key":"zoi261023r26","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2025.4347","article-title":"CONSORT 2025 Statement: Updated Guideline for Reporting Randomized Trials.","volume":"333","author":"Hopewell","year":"2025","journal-title":"JAMA"},{"issue":"3","key":"zoi261023r27","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00259-022-06015-0","article-title":"[68Ga]Ga-DOTA-FAPI-04 PET\/MR in patients with acute myocardial infarction: potential role of predicting left ventricular remodeling.","volume":"50","author":"Zhang","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"zoi261023r28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.132425","article-title":"Potential of 68Ga-FAPI-04 PET\/MR to predict worsening renal function after acute ST-elevation myocardial infarction.","volume":"414","author":"Yi","year":"2024","journal-title":"Int J Cardiol"},{"issue":"3","key":"zoi261023r29","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jcmg.2017.01.008","article-title":"Myocardial infarct size by CMR in clinical cardioprotection studies: insights from randomized controlled trials.","volume":"10","author":"Bulluck","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"issue":"3","key":"zoi261023r30","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s40262-021-01095-x","article-title":"Clinical pharmacokinetics and pharmacodynamics of roxadustat.","volume":"61","author":"Czock","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"18","key":"zoi261023r31","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026232","article-title":"Effects of nicorandil administration on infarct size in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the CHANGE trial.","volume":"11","author":"Qian","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"14","key":"zoi261023r32","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1161\/CIRCULATIONAHA.113.003653","article-title":"Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial.","volume":"128","author":"Ibanez","year":"2013","journal-title":"Circulation"},{"issue":"5","key":"zoi261023r33","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1056\/NEJMoa071142","article-title":"Effect of cyclosporine on reperfusion injury in acute myocardial infarction.","volume":"359","author":"Piot","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi261023r34","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12951-023-02020-z","article-title":"HIF-1a increases the osteogenic capacity of ADSCs by coupling angiogenesis and osteogenesis via the HIF-1a\/VEGF\/AKT\/mTOR signaling pathway.","volume":"21","author":"Song","year":"2023","journal-title":"J Nanobiotechnology"},{"key":"zoi261023r35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.mam.2015.12.004","article-title":"The role of HIF in immunity and inflammation.","volume":"47-48","author":"Cummins","year":"2016","journal-title":"Mol Aspects Med"},{"issue":"3","key":"zoi261023r36","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1097\/HEP.0000000000000569","article-title":"Canonical Wnt signaling promotes HSC glycolysis and liver fibrosis through an LDH-A\/HIF-1a transcriptional complex.","volume":"79","author":"Wang","year":"2024","journal-title":"Hepatology"},{"issue":"1","key":"zoi261023r37","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1186\/s13287-020-01881-7","article-title":"HIF-1a overexpression in mesenchymal stem cell\u2013derived exosomes mediates cardioprotection in myocardial infarction by enhanced angiogenesis.","volume":"11","author":"Sun","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"zoi261023r38","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117567","article-title":"Combined dapagliflozin and roxadustat effectively protected heart and kidney against cardiorenal syndrome\u2013induced damage in rodent through activation of cell stress-Nfr2\/ARE signalings and stabilizing HIF-1a.","volume":"180","author":"Sung","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"7134","key":"zoi261023r39","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/nature05602","article-title":"p53-Induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload.","volume":"446","author":"Sano","year":"2007","journal-title":"Nature"},{"issue":"24","key":"zoi261023r40","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1161\/CIRCULATIONAHA.122.061900","article-title":"Targeting VEGF-A\/VEGFR2 Y949 signaling\u2013mediated vascular permeability alleviates hypoxic pulmonary hypertension.","volume":"146","author":"Zhou","year":"2022","journal-title":"Circulation"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2855122\/quan_2026_oi_261023_1790955538.71111.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:30:24Z","timestamp":1791559824000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2855122"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.37953","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]}}}